WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...

Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic ...

It is common for sponsors to switch digital platforms between clinical trial phases, but sponsors can achieve much by using ...